Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Non/Small Cell Lung Cancer
Recent news which mentions Non/Small Cell Lung Cancer
EQRx's Lung Cancer Candidate Shows Improved Progression-Free Survival Versus Placebo
August 08, 2022
Tickers
EQRX
Tags
Biotech
Non/Small Cell Lung Cancer
Benzinga
From
Benzinga
The Evolution of Lung Cancer Research
May 19, 2022
Tags
Ticker Symbol NYSE: BMY
Adam Schoenfeld
Research, Reports & Publications
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Merck, Athenex Join Forces To Evaluate Oraxol/Keytruda Combo In Lung Cancer
May 16, 2022
Tickers
ATNX
MRK
Tags
Non/Small Cell Lung Cancer
MRK
Briefs
From
Benzinga
Bristol Myers' Neoadjuvant Opdivo/Chemo Improves Event-Free Survival In Early-Stage Lung Cancer Patients
April 11, 2022
Tickers
BMY
Tags
General
News
Phase 3 Trial
From
Benzinga
Lilly Presents Updated Data On Retevmo In Advanced RET Fusion-Positive Lung Cancer
April 01, 2022
Tickers
LLY
Tags
Briefs
LLY
Biotech
From
Benzinga
Why Are Immutep Shares Trading Higher?
March 30, 2022
Tickers
IMMP
Tags
Health Care
IMMP
Market News
From
Benzinga
Cullinan Oncology Lead Cancer Program Shows Confirmed ORR Of 41% In Lung Cancer Setting
March 29, 2022
Tickers
CGEM
Tags
Market News
CGEM
Health Care
From
Benzinga
Merck Lays Out Keytruda Data In Post Surgery Early-Stage Lung Cancer Setting
March 18, 2022
Tickers
MRK
Tags
Benzinga
Non/Small Cell Lung Cancer
Biotech
From
Benzinga
Iovance Receives FDA Allowance For IOV-4001 Study In Two Advanced Cancers
March 16, 2022
Tickers
CLLS
IOVA
Tags
Health Care
IOVA
Penny Stocks
From
Benzinga
Junshi Biosciences - Coherus Toripalimab Chemo Combo Met Survival Endpoints In Lung Cancer Setting
March 15, 2022
Tickers
CHRS
Tags
News
General
Phase 3 Trial
From
Benzinga
BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC
March 08, 2022
Tickers
BNTX
REGN
SNY
Tags
SNY
News
General
From
Benzinga
Spectrum Pharma Highlights Poziotinib Data In Treatment-Naïve Lung Cancer Setting
March 07, 2022
Tickers
SPPI
Tags
General
News
Health Care
From
Benzinga
FDA Approves Bristol Myers' Opdivo Plus Chemo In Neoadjuvant Lung Cancer Setting
March 07, 2022
Tickers
BMY
Tags
Health Care
BMY
Market News
From
Benzinga
Mirati Therapeutics' Adagrasib Application Under FDA Review For Lung Cancer Setting
February 16, 2022
Tickers
MRTX
Tags
General
News
Market News
From
Benzinga
Pfizer's Lorlatinib Scores European Approval In ALK-Positive Lung Cancer
January 28, 2022
Tickers
PFE
Tags
Trading Ideas
Briefs
Non/Small Cell Lung Cancer
From
Benzinga
Amgen's Lumakras Approved In Japan For Pretreated Lung Cancer Patients
January 20, 2022
Tickers
AMGN
Tags
Market News
Health Care
General
From
Benzinga
EQRx's Sugemalimab Shows Significant Overall Survival Benefit In Lung Cancer Settings
January 19, 2022
Tickers
EQRX
Tags
Non/Small Cell Lung Cancer
Benzinga
Biotech
From
Benzinga
Europe Approves Amgen's KRAS-Targeted Lung Cancer Therapy
January 10, 2022
Tickers
AMGN
Tags
News
General
AMGN
From
Benzinga
Merck's Keytruda As Adjuvant Treatment Improves Disease-Free Survival In Lung Cancer Setting
January 10, 2022
Tickers
MRK
Tags
Health Care
Phase 3 Trial
Market News
From
Benzinga
Genprex's Lead Cancer Program Scores Second FDA Fast Track Tag For Lung Cancer Setting
January 03, 2022
Tickers
AZN
GNPX
MRK
Tags
Long Ideas
Penny Stocks
General
From
Benzinga
CytomX Posts Interim Data From Phase 2 Trial Of CD71-Targeting Cancer Candidate
December 21, 2021
Tickers
ABBV
CTMX
Tags
Biotech
Benzinga
Movers
From
Benzinga
Cullinan Oncology Posts Updated Data for CLN-081 in NSCLC EGFR Exon 20 Patients
December 16, 2021
Tickers
CGEM
Tags
Benzinga
Biotech
Market News
From
Benzinga
Janssen Secures Conditional EU Marketing Authorization For Rybrevant in Lung Cancer Setting
December 13, 2021
Tickers
JNJ
Tags
General
News
Health Care
From
Benzinga
Roche Posts Encouraging Follow-up Data From Tiragolumab/Tecentriq Trial In Lung Cancer
December 10, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
Benzinga
Non/Small Cell Lung Cancer
RHHBY
From
Benzinga
Blueprint Medicines Expands Precision Therapy With Lengo Therapeutics Acquisition
November 29, 2021
Tickers
BPMC
Tags
Movers
Health Care
Market News
From
Benzinga
Roche's Gavreto Conditionally Approved In Europe For RET Fusion-Positive Lung Cancer
November 19, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
Health Care
RHHVF
Market News
From
Benzinga
Iovance Shares Tumble After Cell Therapy Data From Lung Cancer Trial
November 12, 2021
Tickers
IOVA
Tags
News
General
Health Care
From
Benzinga
Mirati Posts More Responses For Adagrasib-Keytruda Combo In Lung Cancer Setting
November 09, 2021
Tickers
MRK
MRTX
Tags
Briefs
Trading Ideas
MRTX
From
Benzinga
Bristol Myers' Opdivo Combo Meets Endpoint Goal In Lung Cancer Trial
November 08, 2021
Tickers
BMY
Tags
General
News
Health Care
From
Benzinga
Why Did Calithera Shares Dropped To 52-Week Low In Premarket Friday?
November 05, 2021
Tickers
CALA
Tags
Short Ideas
Biotech
why it's moving
From
Benzinga
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.